GlassScriptPhysician profile
Pooja Mohan Rao
NPI 1750638508
$16,940.91
in general payments reported to CMS, 2019-2025
31 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $376 · 2021: $97.98 · 2022: $277 · 2023: $8,314 · 2024: $4,665 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,140 · Food and Beverage: $3,399 · Travel and Lodging: $2,254 · Consulting Fee: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,140.00 |
| Food and Beverage | $3,398.78 |
| Travel and Lodging | $2,254.17 |
| Consulting Fee | $1,980.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $8,954.94 | 2023-2025 | Rystiggo |
| Grifols USA, LLC | $3,091.95 | 2020-2024 | Gamunex-C |
| Neuropace, INC. | $1,391.87 | 2019 | |
| Biogen, INC. | $531.05 | 2019-2025 | Spinraza, Leqembi |
| Teva Pharmaceuticals USA, INC. | $482.99 | 2023-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $354.92 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $294.67 | 2022-2025 | Xeomin, Inbrija |
| Ge Healthcare | $262.55 | 2025 | |
| Argenx US, INC. | $193.35 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $161.77 | 2022-2025 | Rytary, Crexont |
| Baxter Healthcare | $130.80 | 2024 | Tisseel |
| Kyowa Kirin, INC. | $130.06 | 2023-2024 | Nourianz |
| Tandem Diabetes Care, INC. | $118.51 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alnylam Pharmaceuticals INC. | $102.16 | 2022 | |
| Sarepta Therapeutics, INC. | $92.16 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.11 | 2025 | |
| Neurocrine Biosciences, INC. | $91.19 | 2023-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $72.60 | 2022-2023 | Ampyra, Inbrija |
| Corium, LLC | $47.89 | 2023 | Adlarity |
| Azurity Pharmaceuticals, INC. | $44.30 | 2023 | Horizant |
| Acadia Pharmaceuticals INC | $43.29 | 2025 | Nuplazid |
| Avion Pharmaceuticals | $41.42 | 2023 | Dhivy |
| Abbott Laboratories | $37.43 | 2024 | Infinity |
| Sk Life Science, INC. | $36.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $28.24 | 2023 | Ultomiris |
| Xeris Pharmaceuticals, INC. | $23.73 | 2023 | Keveyis |
| Eisai INC. | $22.40 | 2025 | |
| Ascensia Diabetes Care US INC. | $18.90 | 2023 | |
| Amgen INC. | $17.13 | 2025 | |
| Lilly USA, LLC | $15.00 | 2023 | Amyvid |
| Allergan, INC. | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Mohan Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.